Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
Pharmacological inhibition of...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
Detalles Bibliográficos
Main Authors:
Bekker, P
,
Keshav, S
,
Wei, Z
,
Ertl, L
,
Wang, Y
,
Lai, N
,
Wright, J
,
Ungashe, S
,
Schall, T
Formato:
Journal article
Publicado:
2007
Existencias
Descripción
Títulos similares
Staff View
Títulos similares
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
por: Walters, M, et al.
Publicado: (2010)
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
por: Keshav, S, et al.
Publicado: (2007)
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
por: Bekker, P, et al.
Publicado: (2007)
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
por: Wendt, E, et al.
Publicado: (2015)
MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
por: Ungashe, S, et al.
Publicado: (2008)